Lucas, Claire M <br/><br/>
c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.  [electronic resource] 

 -  Haematologica  May 2015 
 - e179-82 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2014.115691  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Autoantigens--metabolism<br/>Cell Line, Tumor<br/>Enzyme Activation--drug effects<br/>Fusion Proteins, bcr-abl--metabolism<br/>Humans<br/>Intracellular Signaling Peptides and Proteins<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--diagnosis<br/>Membrane Proteins--metabolism<br/>Proto-Oncogene Proteins c-myc--antagonists & inhibitors<br/>RNA Interference<br/>RNA, Small Interfering--genetics<br/>Thiazoles--pharmacology